146 related articles for article (PubMed ID: 9048348)
1. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients.
Parker KP; Mitch WE; Stivelman JC; Macon EJ; Bailey JL; Sands JM
J Am Soc Nephrol; 1997 Feb; 8(2):288-93. PubMed ID: 9048348
[TBL] [Abstract][Full Text] [Related]
2. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients.
Carlini R; Obialo CI; Rothstein M
Am J Hypertens; 1993 Feb; 6(2):103-7. PubMed ID: 8471228
[TBL] [Abstract][Full Text] [Related]
3. Subcutaneous recombinant human erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis.
Pais MJ; Gaspar A; Santana A; Bruges M; Simões J
Perit Dial Int; 1993; 13 Suppl 2():S541-3. PubMed ID: 8399660
[TBL] [Abstract][Full Text] [Related]
4. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients.
Albitar S; Meulders Q; Hammoud H; Soutif C; Bouvier P; Pollini J
Nephrol Dial Transplant; 1995; 10 Suppl 6():40-3. PubMed ID: 8524493
[TBL] [Abstract][Full Text] [Related]
5. Treatment of anaemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo).
Locatelli F; Canaud B; Giacardy F; Martin-Malo A; Baker N; Wilson J
Nephrol Dial Transplant; 2003 Feb; 18(2):362-9. PubMed ID: 12543893
[TBL] [Abstract][Full Text] [Related]
6. Adequacy of dialysis reduces the doses of recombinant erythropoietin independently from the use of biocompatible membranes in haemodialysis patients.
Movilli E; Cancarini GC; Zani R; Camerini C; Sandrini M; Maiorca R
Nephrol Dial Transplant; 2001 Jan; 16(1):111-4. PubMed ID: 11209002
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of erythropoietin with oral iron in peritoneal dialysis and hemodialysis patients.
Raja R; Bloom E; Johnson R
Adv Perit Dial; 1993; 9():177-80. PubMed ID: 8105918
[TBL] [Abstract][Full Text] [Related]
8. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO.
Mittman N; Sreedhara R; Mushnick R; Chattopadhyay J; Zelmanovic D; Vaseghi M; Avram MM
Am J Kidney Dis; 1997 Dec; 30(6):912-22. PubMed ID: 9398141
[TBL] [Abstract][Full Text] [Related]
9. Comparison of intramuscular versus subcutaneous erythropoietin for the treatment of anemia in CAPD patients.
Abreo K; Lubom JA; Collier L; Fleming D; Work J
Adv Perit Dial; 1994; 10():124-8. PubMed ID: 7999809
[TBL] [Abstract][Full Text] [Related]
10. Improved response to erythropoietin in peritoneal dialysis patients as compared to hemodialysis patients: role of iron deficiency.
Raja R; Bloom E; Johnson R; Goldstein M
Adv Perit Dial; 1994; 10():135-8. PubMed ID: 7999811
[TBL] [Abstract][Full Text] [Related]
11. Once weekly versus twice weekly subcutaneous administration of recombinant human erythropoietin in haemodialysis patients.
Lui SF; Wong KC; Li PK; Lai KN
Am J Nephrol; 1992; 12(1-2):55-60. PubMed ID: 1415366
[TBL] [Abstract][Full Text] [Related]
12. Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease.
Muirhead N; Churchill DN; Goldstein M; Nadler SP; Posen G; Wong C; Slaughter D; Laplante P
Am J Nephrol; 1992; 12(5):303-10. PubMed ID: 1488998
[TBL] [Abstract][Full Text] [Related]
13. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients.
Vanrenterghem Y; Bárány P; Mann JF; Kerr PG; Wilson J; Baker NF; Gray SJ;
Kidney Int; 2002 Dec; 62(6):2167-75. PubMed ID: 12427142
[TBL] [Abstract][Full Text] [Related]
14. Subcutaneous recombinant human erythropoietin in children with renal anemia on continuous ambulatory peritoneal dialysis.
Aufricht C; Balzar E; Steger H; Lothaller MA; Frenzel K; Kohlhauser C; Kiss H; Khoss AE; Kernova T
Acta Paediatr; 1993 Nov; 82(11):959-62. PubMed ID: 8111178
[TBL] [Abstract][Full Text] [Related]
15. A 6-month study of low-dose recombinant human erythropoietin alone and in combination with androgens for the treatment of anemia in chronic hemodialysis patients.
Gaughan WJ; Liss KA; Dunn SR; Mangold AM; Buhsmer JP; Michael B; Burke JF
Am J Kidney Dis; 1997 Oct; 30(4):495-500. PubMed ID: 9328363
[TBL] [Abstract][Full Text] [Related]
16. Erythropoietin with oral iron in peritoneal and hemodialysis patients. A comparison in an inner city population.
Raja R; Bloom E; Goldstein M; Johnson R
ASAIO J; 1993; 39(3):M578-80. PubMed ID: 8268603
[TBL] [Abstract][Full Text] [Related]
17. The haematopoietic effect of recombinant human erythropoietin in haemodialysis is independent of the mode of administration (i.v. or s.c.).
De Schoenmakere G; Lameire N; Dhondt A; Van Loo A; Van der Goten J; Duym P; Vanholder R
Nephrol Dial Transplant; 1998 Jul; 13(7):1770-5. PubMed ID: 9681726
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of postdialysis L-carnitine administration and its effect on weekly requiring doses of rHuEPO in hemodialysis patients.
Kadiroglu AK; Yilmaz ME; Sit D; Kara IH; Isikoglu B
Ren Fail; 2005; 27(4):367-72. PubMed ID: 16060121
[TBL] [Abstract][Full Text] [Related]
19. Improvement of erythropoietin-induced hypertension in hemodialysis patients changing the administration route.
Navarro JF; Teruel JL; Marcén R; Ortuño J
Scand J Urol Nephrol; 1995 Mar; 29(1):11-4. PubMed ID: 7618043
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of heme iron polypeptide: sustaining a response to rHuEPO in hemodialysis patients.
Nissenson AR; Berns JS; Sakiewicz P; Ghaddar S; Moore GM; Schleicher RB; Seligman PA
Am J Kidney Dis; 2003 Aug; 42(2):325-30. PubMed ID: 12900815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]